Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Universidad De Guadalajara has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, POPA, ILEANA, who is the busiest examiner for the company with 1 pending office action. The prosecution is localized within 1 distinct art unit.
The presence of 1 pending office action indicates a specific point of engagement with the patent office. Because there is only 1 distinct examiner and 1 distinct art unit, the university's current patent activity is highly focused. POPA, ILEANA is the sole examiner responsible for the university's active biotech prosecution.
The concentration of the workload under a single examiner suggests a streamlined prosecution process. Because there is only 1 busiest examiner pending action, the technical focus of the examination remains narrow. Practitioners working with POPA, ILEANA will find that this individual manages the entirety of the university's currently pending work. This structure allows for a very specific legal strategy tailored to the preferences of a single examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 1 | 21.7% | +15.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17787791 | NANOPARTICLES FOR CANCER TREATMENT | POPA, ILEANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17787791 | NANOPARTICLES FOR CANCER TREATMENT | POPA, ILEANA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17787791 | NANOPARTICLES FOR CANCER TREATMENT | POPA, ILEANA | 1633 | §103 | Final Rejection | — | Pending | Apr 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversidad De Guadalajara has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ileana Popa has the most, with 1 of Universidad De Guadalajara's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
